details

Peer companies

;

Share Market News

Gufic Biosciences is currently trading at Rs. 69.90, up by 1.70 points or 2.49% from its previous closing of Rs. 68.20 on the BSE.The scrip opened at Rs. 69.90 and has touched a high and low of Rs. 69.90 and Rs. 69.00 respectively.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 98.80 on 07-Jan-2019 and a 52 week low of Rs. 51.10 on 08-Aug-2019.Last one week high and low of the scrip stood at Rs. 70.00 and Rs. 66.40 respectively. The current market cap of the company is Rs. 530.80 crore.The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 9.56% and 24.68% respectively.Gufic Biosciences has received Patent Certificate from the Patent Office, the Government of India, for Parenteral Formulations of Levosimendan.Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

The sales slipped to Rs. 876.53 millions for the December 2018 quarter as against Rs. 924.21 millions during the year-ago period.The Net proft of the company remain more or less same to Rs. 58.80  millions from Rs. 61.87 millions ,decline by -4.96%.Operating Profit reported a sharp decline to 121.89 millions from 129.93 millions in the corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 876.53 924.21 -5.16 2585.65 2311.26 11.87 3041.20 2604.18 16.78 Other Income 2.26 6.98 -67.62 11.49 16.55 -30.57 29.43 14.40 104.37 PBIDT 121.89 129.93 -6.19 345.67 310.23 11.42 411.06 243.90 68.54 Interest 23.49 24.69 -4.86 67.51 69.26 -2.53 88.72 63.40 39.94 PBDT 98.40 105.24 -6.50 278.16 256.86 8.29 338.23 180.50 87.39 Depreciation 10.52 10.07 4.47 29.88 29.42 1.56 42.80 36.83 16.21 PBT 87.88 95.17 -7.66 248.28 227.44 9.16 295.43 143.68 105.62 TAX 29.08 33.30 -12.67 88.29 74.56 18.41 135.20 53.47 152.85 Deferred Tax -2.77 -0.04 6825.00 4.67 -9.18 -150.87 12.46 -18.53 -167.24 PAT 58.80 61.87 -4.96 159.98 152.88 4.64 160.23 90.21 77.62 Equity 77.83 77.83 0.00 77.83 77.83 0.00 77.35 77.35 0.00 PBIDTM(%) 13.91 14.06 -1.08 13.37 13.42 -0.40 13.52 9.37 44.31

The revenue zoomed 23.76% to Rs. 784.91 millions for the quarter ended June 2018 as compared to Rs. 634.24 millions during the corresponding quarter last year.Net profit stood at Rs. 39.31  millions  compared to Rs. 35.41 millions in the corresponding previous quarter,high by 11.01%.Operating Profit saw a handsome growth to 93.85 millions from 74.93 millions in the quarter ended June 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 784.91 634.24 23.76 784.91 634.24 23.76 3041.20 2604.18 16.78 Other Income 2.25 0.78 188.46 2.25 0.78 188.46 29.43 14.40 104.37 PBIDT 93.85 74.93 25.25 93.85 74.93 25.25 411.06 243.90 68.54 Interest 19.33 17.55 10.14 19.33 17.55 10.14 88.72 63.40 39.94 PBDT 74.52 68.13 9.38 74.52 68.13 9.38 338.23 180.50 87.39 Depreciation 9.29 9.33 -0.43 9.29 9.33 -0.43 42.80 36.83 16.21 PBT 65.23 58.80 10.94 65.23 58.80 10.94 295.43 143.68 105.62 TAX 25.91 23.39 10.77 25.91 23.39 10.77 135.20 53.47 152.85 Deferred Tax 7.48 -0.65 -1250.77 7.48 -0.65 -1250.77 12.46 -18.53 -167.24 PAT 39.31 35.41 11.01 39.31 35.41 11.01 160.23 90.21 77.62 Equity 77.35 77.35 0.00 77.35 77.35 0.00 77.35 77.35 0.00 PBIDTM(%) 11.96 11.81 1.21 11.96 11.81 1.21 13.52 9.37 44.31

The sales moved up 29.59% to Rs. 884.21 millions for the December 2017 quarter as compared to Rs. 682.29 millions during the year-ago period.Profit for the quarter ended December 2017 rises by 86.72% to Rs. 58.37  millions from Rs. 31.26 millions.OP of the company witnessed a marginal growth to 125.66 millions from 68.24 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 884.21 682.29 29.59 2266.95 1934.95 17.16 2494.39 2023.18 23.29 Other Income 6.37 1.54 313.64 31.52 6.24 405.13 7.95 5.42 46.68 PBIDT 125.66 68.24 84.14 322.57 198.89 62.19 279.46 203.49 37.33 Interest 17.24 14.97 15.16 61.71 42.92 43.78 62.45 53.68 16.34 PBDT 108.42 53.27 103.53 271.61 155.97 74.14 217.01 149.81 44.86 Depreciation 11.46 9.25 23.89 30.56 27.73 10.21 36.83 37.87 -2.75 PBT 96.96 44.02 120.26 241.05 128.23 87.98 180.18 111.91 61.00 TAX 38.59 12.76 202.43 79.85 44.79 78.28 66.04 38.67 70.78 Deferred Tax -1.02 -1.45 -29.66 -10.16 -3.72 173.12 -5.96 -4.26 39.91 PAT 58.37 31.26 86.72 161.20 83.44 93.19 114.14 73.24 55.84 Equity 77.35 77.35 0.00 77.35 77.35 0.00 77.35 77.35 0.00 PBIDTM(%) 14.21 10.00 42.09 14.23 10.28 38.43 11.20 10.06 11.41

Gufic Biosciences is currently trading at Rs. 97.40, up by 1.90 points or 1.99% from its previous closing of Rs. 95.50 on the BSE.The scrip opened at Rs. 94.90 and has touched a high and low of Rs. 103.00 and Rs. 92.85 respectively. So far 299877 shares were traded on the counter.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 103.00 on 30-Nov-2017 and a 52 week low of Rs. 45.00 on 02-Dec-2016.Last one week high and low of the scrip stood at Rs. 103.00 and Rs. 90.10 respectively. The current market cap of the company is Rs. 743.72 crore.The promoters holding in the company stood at 69.98%, while Institutions and Non-Institutions held 8.88% and 21.14% respectively.Gufic Biosciences has received two Patent Certificates from the Intellectual Property India, The Patent Office. The Government of India has granted patents to the company for the following formulations—a freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof and process for preparation of parental formulation of Micafungin Sodium.Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences is currently trading at Rs. 88.90, up by 1.30 points or 1.48% from its previous closing of Rs. 87.60 on the BSE.The scrip opened at Rs. 87.55 and has touched a high and low of Rs. 90.50 and Rs. 86.80 respectively. So far 20916 shares were traded on the counter.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 99.60 on 24-Oct-2017 and a 52 week low of Rs. 40.90 on 17-Nov-2016.Last one week high and low of the scrip stood at Rs. 93.50 and Rs. 85.55 respectively. The current market cap of the company is Rs. 691.51 crore.The promoters holding in the company stood at 69.98%, while institutions and non-institutions held 8.88% and 21.14% respectively.Gufic Biosciences has received an approval for the Scheme of Amalgamation of Gufic Lifesciences with itself. The Board of Directors of the Company at its meeting held on November 09, 2017 has approved the same.Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences is currently trading at Rs. 72.30, up by 3.75 points or 5.47% from its previous closing of Rs. 68.55 on the BSE.The scrip opened at Rs. 71.85 and has touched a high and low of Rs. 73.75 and Rs. 71.25 respectively. So far 80,000 shares were traded on the counter.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 77.40 on 18-May-2017 and a 52 week low of Rs. 33.30 on 29-Sep-2016.Last one week high and low of the scrip stood at Rs. 73.75 and Rs. 64.00 respectively. The current market cap of the company is Rs. 558.85 crore.The promoters holding in the company stood at 69.98%, while Institutions and Non-Institutions held 0.20% and 29.82% respectively.Gufic Biosciences has received two Patent Certificates from the Intellectual Property India, The Patent Office. The Government of India, has granted patents to the company for the following formulations - ‘A Freeze Dried Pharmaceutical Composition and Process for Preparation Thereof i.e., Process for Preparation of Parental Formulation of Anidulafungin’ and ‘A Freeze Dried Parental Composition of Tigecycline and Process for Preparation Thereof’. The company is in the process of applying the above patents in other countries as well.Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences has submitted a copy of notice published in the newspapers on December 15, 2016 as required under IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends of the Company for last seven years, failing which their shares would be transferred to Investor Education and Protection Fund (IEPF) Suspense account, in accordance with section 124 of the Companies Act, 2013 read with Rules framed there under.The above information is a part of company’s filings submitted to BSE.

Gufic Biosciences has submitted a copy of Standalone Statement on Impact of Audit Qualifications for the period ended March 31, 2016.The above information is a part of company’s filings submitted to BSE.

Gufic Biosciences has informed that Santoshkumar Sharma, Company Secretary and Compliance officer of the Company has resigned from the Company with effect from the December 02, 2015.The above information is a part of company’s filings submitted to BSE.

Gufic Biosciences has submitted a copy of Scrutinizers Report on remote e-voting, Consolidated Scrutinizers Report for Remote e-voting & Poll and Form No. MGT 13 of the Company.The above information is a part of company’s filings submitted to BSE.

Gufic Biosciences has submitted a copy of updated financial results (With Denomination) for the period ended June 30, 2015.The above information is a part of company’s filings submitted to BSE.